COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum
Magdalena plans to submit IND application in early 2025 to FDA for next-generation psychoactive drug for mental health such as ADHD and schizophrenia. Jaguar Health presents at BIO Investor Forum to discuss lead botanical drug candidate MB2500 -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial
Jaguar Health, Inc. announced a late-breaking abstract on diarrhea management from a placebo group study in breast cancer patients. Further FDA discussions planned -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer
Jaguar Health, Inc. announces positive results for crofelemer in breast cancer patients from OnTarget trial, to be presented at an oncology conference with potential for future submissions. Crofelemer also shows promise in IBS-D patients
